Inmune Bio Inc.
INMB· Nasdaq
Released Aug 6, 2026, after the close
10-Q filed Aug 6, 2026, 37 days after period end · 0001213900-26-086135
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $46.00K |
| Net Income | -$1.27M | -$24.46M | -$9.75M | -$6.50M |
| EPS Diluted | -$0.05 |
Inmune Bio Inc. · CIK 1711754 · Engraved from SEC EDGAR
| -$1.05 |
| -$0.50 |
| -$0.36 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.